Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration
NCT05439629 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 488
Last updated 2025-12-08
Summary
A non-inferiority design was used to conduct a randomized, double-blind, parallel-controlled multi-center study. A total of 488 subjects with neovascular (wet) age-related macular degeneration (w-AMD) were planned to be enrolled. Qualified subjects were divided into experimental group and control group in a 1:1 ratio, and stratified randomized according to the letter value of baseline period and whether the eyes had received anti-VEGF drug treatment. The experimental group received BAT5906 injection. The control group received Lucentis® treatment. Only 1 eye per subject was included in this study.
Conditions
Interventions
- DRUG
-
BAT5906 injection
4.0 mg/eye/time, 50 μl, intravitreal injection
- DRUG
-
Lucentis
0.5 mg/eye/time, 50 μl, intravitreal injection
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Youxin Chen, Doctor · Peking Union Medical College
-
Xiaolin Liu, Doctor · Affiliated Optometry Hospital of Wenzhou Medical University
-
Mingwei Zhao, Doctor · Peking University People's Hospital
-
Yi Chen, Doctor · China-Japan Friendship Hospital
-
Hong Dai, Doctor · Beijing Hospital
-
Yong Tao, Doctor · Beijing Chao Yang Hospital
-
Linna Lu, Doctor · The Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
-
Hongping Cui, Doctor · Shanghai Oriental Hospital
-
Xiaolin Liang, Doctor · Sun Yat-sen Ophthalmic Center, Sun Yat-sen University
-
Pengxia Wan, Doctor · First Affiliated Hospital, Sun Yat-Sen University
-
Yuqing Lan, Doctor · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
-
Haoyu Chen, Doctor · Shantou University-Chinese University of Hong Kong Joint Shantou International Eye Centre
-
Xiyuan Zhou, Doctor · The Second Affiliated Hospital of Chongqing Medical University
-
Xiaohong Meng, Doctor · The First Affiliated Hospital of Army Medical University (Southwest Hospital)
-
Jinglin Yi, Doctor · The Affiliated Eye Hospital of Nanchang University
-
Hongmei Zheng, Doctor · People's Hospital of Wuhan University (Hubei Provincial People's Hospital)
-
Liuhua Tong, Doctor · People's Hospital of Quzhou
-
Zongming Song, Doctor · Henan Eye Center (Henan Eye Hospital)
-
Shenzhi Liang, Doctor · The First Affiliated Hospital of Zhengzhou University
-
Junfeng Mao, Doctor · Xiangya Hospital of Central South University
-
Xiangwen Shu, Master · Jinan Second People's Hospital
-
Yuanbin Li, Doctor · Yantai Yuhuangding Hospital
-
Shanjun Cai, Doctor · Zunyi Medical College
-
Xian Wang, Doctor · Affiliated Hospital of Guizhou Medical University
-
Xu Li, Master · The Fourth People's Hospital of Shenyang
-
Rongrong Zhu, Bachelor · Affiliated Hospital of Nantong University
-
Wei Wei, Doctor · Jiangsu Provincial Hospital of Traditional Chinese Medicine
-
Yabin Sun, Doctor · The First Hospital of Jilin University
-
Liming Tao, Doctor · The Second Hospital of Anhui Medical University
-
Hongjian Ma, Doctor · Aier Eye Hospital, Guangzhou
-
Yaohong Wu, Doctor · Second Hospital of Shanxi Medical University
-
Jian Guo, Doctor · First Affiliated Hospital of Fujian Medical University
-
Xiaoling Luo, Doctor · Shenzhen People's Hospital
-
Qiuhong Liu, Doctor · The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
-
Xinquan Liu, Doctor · Shanghai University of Traditional Chinese Medicine
-
Lifei Wang, Doctor · Hebei Provincial Eye Hospital
-
Dan Zhu, Doctor · The Affiliated Hospital of Inner Mongolia Medical University
-
Xuemei Pan, Master · The Affiliated Eye Hospital of Shandong University of Chinese Medicine
-
Yanfei Qiu, Doctor · Pingxiang People's Hospital
-
Zhen Zhang, Doctor · Xuzhou Central Hospital
-
Jingbo Li, Doctor · Luoyang Third People's Hospital
-
Xinyan Xu, Master · Weifang Eye Hospital
-
Lan Li, Master · The First People's Hospital of Kunming
-
Hongxia Yang, Bachelor · Jinzhong First People's Hospital
-
Miaoqin Wu, Doctor · Zhejiang Provincial People's Hospital
-
Zhaozeng Lu, Doctor · Huashan Hospital
-
Gangfeng Cui, Doctor · Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University
-
Quanyong Yi, Doctor · Ningbo Eye Hospital
-
Ruifeng Wang, Doctor · The Second People's Hospital of Zhengzhou
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 50 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-07-07
- Primary Completion
- 2025-04-22
- Completion
- 2025-04-22
Countries
- China
Study Locations
More Related Trials
-
A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)
NCT02698566 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration
NCT02121353 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD
NCT05480293 ·Status: UNKNOWN ·Phase: PHASE3
-
Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD
NCT03805100 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients
NCT00826371 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)
NCT03150589 ·Status: COMPLETED ·Phase: PHASE3
-
The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration
NCT00857259 ·Status: TERMINATED ·Phase: PHASE2
-
Lucentis in Advanced Macular Degeneration
NCT00896779 ·Status: COMPLETED ·Phase: PHASE2
-
Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis
NCT00804934 ·Status: COMPLETED
-
Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments
NCT00590694 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Analysis of naïve Patients With Age-related Macular Degeneration Neovascular Type and Treated With Ranibizumab (Lucentis®) in Treat-and-extend at the CHU Brugmann.
NCT04988178 ·Status: COMPLETED
-
Pilot Study of Lucentis Combined With Proton Beam Irradiation in Treating Wet Age-related Macular Degeneration
NCT00517010 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration
NCT00539734 ·Status: COMPLETED ·Phase: NA
-
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial
NCT00593450 ·Status: COMPLETED ·Phase: PHASE3
-
Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
NCT01810042 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration
NCT01628354 ·Status: COMPLETED ·Phase: PHASE4
-
Genetic Polymorphisms in Ranibizumab Treatment in Wet Age-Related Macular Degeneration (AMD)
NCT01676506 ·Status: UNKNOWN ·Phase: NA
-
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
NCT01940900 ·Status: TERMINATED ·Phase: PHASE3
-
Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy
NCT01255774 ·Status: UNKNOWN ·Phase: PHASE3
-
Treatment -Resistant Neovascular Age-Related Macular Degeneration
NCT02332941 ·Status: COMPLETED ·Phase: PHASE1
-
Study EvAluating Genotypes While Using Lucentis 2
NCT01464723 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration
NCT02036723 ·Status: WITHDRAWN ·Phase: PHASE3
-
Efficacy Study of Lucentis in the Treatment of Retinoblastoma
NCT01899066 ·Status: UNKNOWN ·Phase: PHASE2
-
Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV
NCT00429962 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD
NCT00574093 ·Status: COMPLETED ·Phase: PHASE2